The FDA has accepted an orphan new drug application for Brilliant Blue G ophthalmic solution for staining the internal limiting membrane, Dutch Ophthalmic Research Center announced in a press release.
If approved, Brilliant Blue G, intended to stain and distinguish the ILM from the retina to facilitate removal, will be the first FDA-approved product for this indication, the release said.
“DORC has always worked closely with surgeons around the world to develop practical advancements in treating eye disorders” Thierry Leclercq, CEO of DORC International, said in the release. “The

Full Story →

The FDA has accepted an orphan new drug application for Brilliant Blue G ophthalmic solution for staining the internal limiting membrane, Dutch Ophthalmic Research Center announced in a press release.
If approved, Brilliant Blue G, intended to stain and distinguish the ILM from the retina to facilitate removal, will be the first FDA-approved product for this indication, the release said.
“DORC has always worked closely with surgeons around the world to develop practical advancements in treating eye disorders” Thierry Leclercq, CEO of DORC International, said in the release. “The

Full Story →